Bristol-Myers Squibb Company (BMY)
Overview
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis. It also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a protein-bound chemotherapy product; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; and Empliciti for the treatment of multiple myeloma. In addition, the company offers Zeposia to treat relapsing forms of multiple sclerosis; Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Inrebic, an oral kinase inhibitor indicated for the treatment of adult patients with myelofibrosis; and Onureg for the treatment of adult patients with AML. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York.
Explore More Data
Key Information
Stock Snapshot (Updated: Nov 05 04:00 PM EST)
Capital Structure (Updated: Nov 05 04:00 PM EST)
Calendar Events (Upcoming Earnings & Revenue Forecasts)
| Earnings | |
| Earnings Date | 2025-10-30 |
| Earnings Call | 2026-02-05 |
| Avg EPS Estimate | 1.6544 |
| Low EPS Estimate | 1.56 |
| High EPS Estimate | 1.7962 |
| Revenue | |
| Avg Revenue Forecast | 12,274,887,660 |
| Low Revenue Forecast | 12,023,000,000 |
| High Revenue Forecast | 12,533,000,000 |
BMY Liquidity Indicators Shows key metrics that reflect cash availability and short-term payment ability
| Field | Value | Description |
|---|---|---|
| Cash Holdings | $16,501,999,616 | Cash on hand, which directly shows a company's ability to meet short-term obligations. |
| Quick Ratio | 1.106 | The quick ratio, which excludes inventory, measures short-term solvency; a value above 1 is considered relatively safe. |
| Current Ratio | 1.266 | The current ratio, calculated as current assets divided by current liabilities; the higher the value, the better the liquidity. |
| Total Debt | $51,041,001,472 | Total liabilities, used together with cash and liquidity ratios to assess debt burden. |
BMY Profitability Indicators Shows key metrics that reflect overall earnings, margins, and core business profitability
| Field | Value | Description |
|---|---|---|
| EBITDA | $19,217,000,448 | EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization), which measures the profitability of core operations. |
| Operating Cash Flow | $16,620,999,680 | Operating cash flow, which reflects a company's cash-generating ability. |
| Free Cash Flow | $14,718,374,912 | Free cash flow, after deducting capital expenditures, which can be used for dividends or reinvestment. |
| Gross Margin | 73.15% | Gross margin; a higher value indicates stronger product profitability. |
| Operating Margin | 31.57% | Operating margin; slightly negative, indicating high operating costs. |
| Profit Margin | 12.57% | Net profit margin, which reflects overall profitability. |
BMY Leverage & Financial Health Indicators Shows key metrics that reflect debt levels, liquidity, and overall financial stability
| Field | Value | Description |
|---|---|---|
| Debt/Equity Ratio | 274.41% | Low leverage level, indicating the company has low debt pressure. |
| Total Debt | $51,041,001,472 | Used together with cash and EBITDA to assess debt-paying ability. |
BMY Growth Indicators Shows key financial metrics that reflect profitability, cash flow, and business expansion
| Field | Value | Description |
|---|---|---|
| Revenue Growth (YoY) | 2.80% | Rapid revenue growth, indicating fast business expansion. |
| Earnings Growth (YoY) | 80.90% | Significant EPS growth, indicating rapid improvement in profitability. |
Financial Data for BMY (Key ratios, margins, and cash flow)
| Field | Value | Description |
|---|---|---|
| Current Price | $46.47 | Latest stock trading price |
| Price Target (High) | $68 | Analyst highest expected price |
| Price Target (Low) | $36 | Analyst lowest expected price |
| Price Target (Average) | $53.29 | Average target price across analysts |
| Price Target (Median) | $52 | Median of target prices |
| Average Rating Score | 2.69 | Average analyst rating (1=Strong Buy, 5=Sell) |
| Consensus Recommendation | hold | Consensus rating |
| Analyst Coverage Count | 21 | Number of analysts providing estimates |
| Cash Holdings | $16,501,999,616 | Total cash held by the company |
| Cash per Share | $8.11 | Cash value per outstanding share |
| Total Debt | $51,041,001,472 | Company's total debt |
| Quick Ratio | 1.106 | Ability to cover short-term liabilities (excludes inventory) |
| Current Ratio | 1.266 | Overall short-term liquidity |
| Debt/Equity Ratio | 274.41% | Leverage ratio: Debt / Equity |
| EBITDA | $19,217,000,448 | Earnings before interest, taxes, depreciation & amortization |
| Total Revenue | $48,034,000,896 | Total company revenue |
| Revenue per Share | $23.627 | Total revenue divided by shares outstanding |
| Gross Profit | 73.15% | Revenue minus cost of goods sold |
| Return on Assets | 9.39% | Net income / Total assets |
| Return on Equity | 33.78% | Net income / Shareholder equity |
| Earnings Growth (YoY) | 80.90% | Year-over-year EPS growth |
| Revenue Growth (YoY) | 2.80% | Year-over-year revenue growth |
| Gross Margin | 73.15% | Gross profit / Total revenue |
| EBITDA Margin | 40.01% | EBITDA / Revenue |
| Operating Margin | 31.57% | Operating income / Revenue |
| Profit Margin | 12.57% | Net income / Revenue |
| Free Cash Flow | $14,718,374,912 | Cash left after capital expenditures |
| Operating Cash Flow | $16,620,999,680 | Cash from core business operations |
| Currency | USD | Reported in US dollars |
| Last Updated | 2025-11-05 | Data source from Yahoo |